To evaluate the contribution of candidate gene association studies to the understanding of genetic susceptibility to childhood acute lymphoblastic leukemia we conducted a systematic review and meta-analysis of published studies (January 1996-July 2009. Studies had to meet the following criteria: be case-control design, be studied by two or more studies, not be focused on HLA antigen genetic markers and be published in English. We identified 47 studies of polymorphic variation in 16 genes and acute lymphoblastic leukemia risk. To clarify the impact of individual polymorphisms on risk, pooled analyses were performed. Of the 25 polymorphic variants studied, significant associations (P<0.05) were seen in pooled analyses for eight variants: GSTM1 (OR =1.16; 95%CI: 1.04-1.30), MTRR A66G (OR=0.73, 95%CI:0.59-0.91), SHMT1 C1420T (OR=0.79, 95%CI: 0.65-0.98), RFC1 G80A (OR=1.37, 95%CI: 1.11-1.69), CYP1A1*2A (OR=1.36, 95%CI:1.11-1.66), CYP2E1*5B (OR=1.99, 95%CI:1.32-3.00) NQO1 C609T (OR=1.24, 95%CI:1.02-1.50) and XRCC1 G28152A (OR=1.78, 95%CI:1.32-2.42). These findings should, however, be interpreted with caution as the estimated false-positive report probabilities (FPRP) for each association were not noteworthy (i.e. FPRP>0.2). While candidate gene analyses are complementary to genome-wide association studies, future analyses should be based on sample sizes commensurate with the detection of small effects and attention needs to be paid to study design.
Introduction
Acute leukemia is the major pediatric cancer in developed countries, affecting between 30-45 per 1,000,000 children each year. 1 Dysregulated immune response to infection may be a cause of childhood acute lymphoblastic leukemia (ALL) 2 and epidemiological data are consistent with transplacental carcinogen exposure as a basis for infant leukemia associated with MLL gene fusion, 3 but the role of environmental carcinogenesis in ALL is currently undefined. It is, however, likely that the risk of ALL from environmental exposure is influenced by co-inheritance of multiple low-risk variants.
The commonest method for identifying common low-risk variants is through association studies. These are based on comparing the frequency of polymorphic genotypes in cases and controls. Alleles positively associated with the disease are analogous to risk factors in epidemiology and may be causally related to disease risk or in linkage disequilibrium with disease-causing variants. There are a number of different methods of analyzing the risk associated with a specific variant. For simple bi-allelic polymorphisms, the odds ratio of disease can be derived by comparing allele frequencies in cases and controls. This approach is, however, less powerful than a comparison of frequencies of the three genotypes among cases and controls using homozygosity of the "wild-type allele" as the reference group. Where homozygotes are rare, it is common to combine the heterozygotes and homozygotes together; but this is only appropriate if a dominant model can be presumed. Similarly, combining heterozygotes with wild-type homozygotes is only appropriate if alleles act recessively.
Excluding HLA, the genetic candidates that have been evaluated as susceptibility genes for childhood ALL to date can be broadly delineated into those coding for carcinogen metabolism enzymes, folate metabolism enzymes, DNA repair proteins, and others. Table 1 details the candidate gene polymorphisms that have been reviewed. For clarity the position and standard nomenclature of each polymorphism is provided.
this context, functional polymorphisms in xenobiotic metabolizing enzymes have been postulated to be of relevance in determining susceptibility to ALL. 4 The first and obligatory step in the activation of arylamines is N-hydroxylation by phase-I enzymes that include cytochrome P4501A1 (CYP1A1; MIM 108330). 5, 6 The glutathione S-transferases are a family of phase-II enzymes responsible for the detoxification of mutagenic electrophiles including polyaromatic hydrocarbons (PAHs). Homozygotes for null alleles (deletion) of GSTM1 (MIM 138350) and GSTT1 (MIM 600436) have absent activity of the respective enzyme. DNA-adduct formation and rates of somatic mutation have been reported to be increased in carriers of null alleles. 7 Other metabolic gene variants that have been investigated as risk factors for ALL include polymorphisms in NQO1 (NADPH:quinone oxidoreductase; MIM 125860) a cytosolic enzyme catalyzing reduction of quinones and prevention of their participation in redox cycling and thus in oxidative stress. 8 Variation in MDR1 (MIM 171050) which encodes the P-glycoprotein (P-gp) has also been studied as a possible risk factor for childhood ALL on the basis that it provides a cellular defense against toxic xenobiotic compounds. 
Folate metabolism genes
Leukemia commonly arises as a result of DNA translocation, inversions or deletions in genes regulating lymphocyte development. The formation of translocations in leukemia are thought to involve DNA double-strand break formation by means other than aberrant V(D)J recombinase activity. 10 Folate deficiency has been associated with uracil misincorporation into DNA and double strand breaks during uracil excision repair thus potentially increasing the risk of chromosomal aberration. 11 Pregnancy is a time of extreme folate requirement and supplementation in pregnancy has been reported to afford protection against childhood ALL.
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Dysfunctional folate metabolism is, therefore, an attractive candidate in the etiology of ALL as the most common translocations in infant leukemia (MLL-AF4) and in common childhood ALL (TEL-AML1) occur in utero in most, if not all, patients. 13 Central to folate metabolism are the enzymes 5,10-methylenetetrahydrofolate reductase (MTHFR; MIM 607093), methionine synthase (MTR alias MS; MIM 156570) and methionine synthase reductase (MTRR; MIM 602568). These genes are characterized by functional polymorphisms and it has been postulated that these variants may impact on ALL risk through affecting folate metabolism. A similar rationale for evaluating vari- 
DNA repair genes
XRCC1 (X-Ray repair-cross complementing group 1; MIM 194360) is believed to play a role in DNA single strand repair by forming protein complexes with DNA repair associated proteins.
14 Polymorphic variants in XRCC1 may, therefore, play a role in ALL through aberrant DNA repair. Polymorphic variants in other DNA repair genes, including ERCC2 (excision repair-complementing group 2; MIM 126340), mutations which cause xeroderma pigmentosum (MIM 278700), trichothiodystrophy (MIM 601675) and Cockayne syndrome (MIM 216400) 15 have also been evaluated as risk factors for ALL for similar reasons.
Although some polymorphic variants have only been examined once, most have been evaluated as risk factors in several studies but often with discordant findings. Furthermore, many of the studies have been based on small sample sizes with limited power to robustly demonstrate a relationship with ALL risk. To gain better insight into the impact of polymorphic variants on risk of childhood ALL, we have undertaken a systematic review of published studies and used standard meta-analysis techniques according to Cochrane 16 and PRISMA 17 guidelines to derive a more precise estimate of the individual variants. The implications of findings for future research on predisposition to ALL are discussed.
Design and Methods

Study identification
A literature search for studies reporting on the association between polymorphic variants and risk of childhood ALL was conducted using the electronic database PubMed from January 1996 up to the end of June 2009 (www.ncbi.nml.nih.gov/pubmed). The search strategy used the key words "acute lymphoblastic leukemia, genetic, association, case, control, polymorphism, risk". We searched for any additional studies in the bibliographies of identified publications, including previous review articles and meta-analyses.
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Selection criteria
Studies were eligible if they were based on unrelated individuals and examined the association between childhood ALL and polymorphic genotype. Only studies published as full-length articles or letters in peer-reviewed journals in English were included in the analysis.
Data extraction
Data for analyses, including study design, sample size, ethnicity, as well as allele and genotype frequencies, were extracted from the published articles and summarized in a consistent manner to aid comparison. When a study reported results on different subpopulations according to ethnicity, we considered each sub-population as a separate study in the meta-analyses.
Statistical analysis
Raw data of genotype frequencies, without adjustment, were used for calculation of the study-specific estimates of odds ratio (OR) and 95% confidence interval (CI). Cochran's Q statistic was used to test for heterogeneity, and the percentage variability of the pooled OR attributable to heterogeneity between studies was quantified using the I 2 statistic; large heterogeneity is typically defined as I 2 ≥ 75%. A P value of >0.05 for the Q test was considered to indicate a lack of heterogeneity across studies and for these analyses the pooled estimation of ORs of each study was calculated by the fixed effects model (Mantel-Haenszel methods). 23 For results showing high heterogeneity, the random effects model (DerSimonian and Laird's method) 24 was used. The significance of the pooled OR was determined by the z-test and P<0.05 was considered as statistically significant. An estimate of the potential publication bias was conducted by examination of funnel plots. An asymmetric plot is reflective of publication bias. The funnel plot symmetry was assessed by Egger's test 25 based on inversevariance weighted regression of the standardized effect sizes (OR/standard error (SE) of OR) on their precision (1/SE) to test whether the intercept deviates significantly from zero; P<0.05 was considered indicative of statistically significant publication bias.
To test for population stratification, the distribution of genotypes in control subjects of each individual population was tested for departure from Hardy-Weinberg equilibrium [HWE] by means of the χ 2 test.
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For each statistically significant association identified, we estimated the false positive reporting probability (FPRP). 27 The FPRP value is determined by the P value, the prior probability for the association, and statistical power. We calculated FPRP assuming a prior of 0.001 as previously proposed for candidate gene analyses. 28 Statistical power was based on the ability to detect an OR of 1.2 and 1.5 (or reciprocal), with α equal to the observed P value. To evaluate whether the association was noteworthy, we imposed an FPRP cut-off value of 0.2, advocated for summary analyses. 27 Hence, FPRP values less than 0.2 were considered to indicate robust associations.
All statistical analyses were undertaken using STATA version 10.0 (Stata Corporation, College Station, TX, USA).
Results
Characteristics of published studies
We retrieved 267 published studies using our search criteria ( Figure 1 ). Forty-seven of these studies met our predetermined criteria for inclusion. These 47 publications detailed 25 polymorphisms in 16 genes (Table 1 ). All the studies were essentially of similar design, although different types of controls have been analyzed (Online Supplementary Table S1 ). In the final group, three studies [29] [30] [31] sub-grouped cases and controls according to ethnicity and seven studies [32] [33] [34] [35] [36] [37] [38] grouped subjects according to ethnicity but did not present data on genotype and risk for the different subgroups. We did not identify any overlapping studies. The ORs of ALL associated with each polymorphism in individual studies are detailed in the Online Supplementary Table S2 .
Meta-analysis
Pooling data from the 17 studies 29, 33, [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] which have examined MTHFR C677T provided no evidence for a relationship between genotype and risk ( Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2 ). There was evidence of population stratification in the studies reported by Wiemels et al. 38 and Balta et al., 40 as controls showed evidence of departure from HWE (P=0.02, 0.05). The pooled ORs were, however, unchanged excluding these studies from the meta-analyPolymorphisms acute lymphoblastic leukemia risk haematologica | 2010; 95 (8) sis. MTHFR A1298C has been evaluated in 14 studies. 29, 33, 38, 39, 42, [44] [45] [46] [47] [48] [49] [50] [51] Pooled analysis provided no evidence for a relationship between A1298C and ALL risk (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table  S2) . Similarly pooling data from the four studies of the MTR A2756G polymorphism 42, 44, 47, 52 provided no support for a relationship between A2756G genotype and risk (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2 ).
The MTRR A66G polymorphism had been evaluated in three studies (Online Supplementary Figures S1 and S2 ; Online Supplementary Table S2) . 42, 47, 52 Pooling data from the three studies (Table 2) 52 however, showed deviation from HWE (P=0.05) and excluding this study provided no evidence for an association between MTRR A66G and ALL risk (data not shown).
SHMT1 C1420T has been studied as a risk factor for ALL in two studies. 42, 52 Pooling data from both studies provided evidence for an association between the heterozygosity and risk (OR=0. 79 RFC1 G80A has also been evaluated in two studies (Online Supplementary Figure S2 ; Table 2; Online  Supplementary Table S2) . 42, 52 One study showed heterozygosity, homozygosity and carrier status to be associated with an increased ALL risk ( Figures S1 and S2) . Evidence for an association between homozygosity and risk was not apparent under a random effects model (OR=1.44, 95% CI: 0.74-2.8).
The four studies 42, 43, 47, 52 of the TS 2R>3R provide no evidence for a relationship between this polymorphism and ALL risk (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2) .
Seven studies 35, 36, [53] [54] [55] [56] [57] have evaluated NQO1 C609T as a risk factor for ALL (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S1 ). The study by Lanciotti et al. 53 only provided data on 609T carrier status. One study 57 showed a significant relationship between heterozygosity and risk while two studies showed a significant association for carrier status 36, 57 (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2 ). Pooling data from all seven studies, however, provided no evidence of a relationship between NQO1 C609T genotype and risk (Online Supplementary Figure S1 ). Controls in the study by Sirma et al. 56 showed evidence of population stratification (P=0.01). In pooling data from the six other studies (Table  2 ; Online Supplementary Figure S2) , there was evidence for a relationship between carrier status and risk (1.24, 95% CI: 1.02-1.50, P=0.03; Phet=0.49, I2=0%) but no relationship with either hetero-or homozygosity (data not shown).
Two studies 54, 57 have examined the relationship between NQO1 C465T and ALL risk ( Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2) ; pooled analyses provided no evidence for a relationship between genotype and risk (Online Supplementary Figure S1 ).
Fifteen studies [30] [31] [32] 35, 37, 40, [58] [59] [60] [61] [62] [63] [64] have examined the relationship between GSTM1 and GSTT1 and ALL risk ( Table S2) . Five of the studies reported a statistically significant increased risk associated with GSTM1 deletion. The pooled OR for GSTM1 was significant (Online Supplementary Figure S2) , under both fixed (OR=1.16, 95%CI: 1.04-1.30, P=0.008; Phet<0.01, I 2 =13%) and random effects models (OR=1.26, 95% CI: 1.05-1.51). There was, however, evidence of publication bias (P<0.01), with four of the smallest studies showing a significant association but with no effect being observed in the larger studies (Online Supplementary Figure S3) . Across all studies no evidence for a relationship between GSTT1 null genotype and ALL risk was shown (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2) .
Seven studies 32, 35, 37, 40, 53, 65, 66 have examined GSTP1 A1578G and ALL risk ( Table 2 ; Online Supplementary Figure  S1 ; Online Supplementary Table S2 ). Pooling data from the seven studies provides no evidence of a relationship between genotype and risk (Online Supplementary Figure  S1 ; Table 2 ). Similarly, pooling of data from the two studies which have examined GSTP1 C2293T as a risk factor provides no support for an association between this variant and ALL ( Figure S2) . While there was evidence of between study heterogeneity, an association was still shown under a random effects model, with respective ORs of 1.38 (95% CI: 1.03-1.40) and 1.36 (95% CI: 1.01-1.84).
Of the three studies 60, 61, 67 which evaluated CYP1A1*2B (A4889G) as a risk factor, one study showed a significant association between the A4889G and increased risk (Online Supplementary Figure S1 ; Online Supplementary Table  S2 ). Pooled data from the three studies, however, provided no evidence for relationship between CYP1A1*2B genotype and risk ( Table 2) .
None of the three studies [59] [60] [61] of CYP2D6*4 (G1934A) showed a relationship with ALL risk (Online Supplementary  Figure S1 ; Online Supplementary Table S2) . Similarly, pooling data from the three studies provided no evidence for an association (Table 2 ; Online Supplementary Figure S1 ). Two studies of CYP2D6*3 (del 2637) also found no evi- Figure S1 ; Online Supplementary Table S2) . Pooling data from all four studies (Table 2 ; Online Supplementary Figure S2) Figure S1 ; Online Supplementary Table S2 ). Homozygosity for TT was associated with a statistically significant increased risk in one study. 69 In the pooled analysis there was, however, no evidence of an association with risk ( Table 2 ). While the controls analyzed by Jamroziak et al. 70 showed evidence of departure from HWE (P=0.04), findings were unaffected excluding this study from the meta-analysis (data not shown).
Pooling data from the two studies 34, 70 of the triallelic variant MDR1 G2677T/A provides no evidence for a relationship between this variant and ALL risk ( Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2) .
Three studies [73] [74] [75] have evaluated XRCC1 polymorphisms C26304T and G28152A (Online Supplementary Figure S1 ; Online Supplementary Table S2) . A significant association between XRCC1 C26304T carrier status/homozygosity and elevated risk was shown in two studies. 74, 75 Pooling data from the three studies did not, however, provide evidence of a relationship between the C26304T genotype and risk (Table 2 ; Online Supplementary Figure S1) . Two of the three studies showed evidence of an association between XRCC1 28152A and increased risk (Online Supplementary Figure S1 ). Pooling data from all three studies (Table 2 ; Online Supplementary Figure S2) 74, 75 and pooling data also provided no evidence of a relationship (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table  S2) . Similarly no significant association between ERCC2 G23591A and A35931C genotype and risk was shown in two studies 73, 75 (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2) .
Acute lymphoblastic leukemia is genetically heterogeneous, hence some associations may be subtype specific. Only five studies examined the relationship between Bcell ALL and risk. 30, 40, 41, 44, 64 Among the three studies 40, 41, 44 that looked at MTHFR C677T and risk, one study had irregularities in the genotype data presented 40 hence data from the study could not be pooled. Combining data from the other two studies showed that C677T was not significantly associated with risk (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2) . Of the three studies 30, 40, 64 which examined the relationship between GSTM1 and risk of B-cell ALL, only two 30, 40 had extractable genotype data. One of the studies was significantly associated with risk. Pooling data from both studies the OR was 0.80 (95% CI: 0.66-0.99, P=0.037; Phet<0.001, I 2 =92%). However, the association was not significant (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2 ) under a random effects model (OR=1.22, 95% CI: 0.38-3.89, P=0.742). Two studies 30, 40 evaluated GSTT1 and risk of B-cell ALL and pooling data from these showed no evidence of an association with risk (Table 2 ; Online Supplementary Figure S1 ; Online Supplementary Table S2) .
To evaluate the robustness of the 16 significant findings from the pooled analyses, we calculated FPRP conditional on a pre-specified prior probability of 0.001. None of the results can be considered noteworthy on the basis of assumptions (Table 2 ). For example, although the summary OR from the pooled analysis of XRCC1 G28152A indicated a statistically significant positive association with risk (OR, 1.78; 95% CI, 1.32-2.42), the FPRP was 0.63 which was much higher than our cut off for noteworthiness (<0.2) for pooled analyses.
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Discussion
It is clear that substantial research has been carried out evaluating polymorphic variants in a number of specific genes as susceptibility alleles for ALL. Has this been worthwhile? While our meta-analysis provides support for variation at GSTM1, MTRR, SHMT1, RFC1, CYP1A1, CYP2E1, NQO1 and XRCC1 as risk determinants for ALL, these data should be interpreted with caution as the associations are not robust on the basis of FPRP estimates.
It is possible to draw a number of conclusions from the current data. Of the 25 variants examined to date, few have been reported as statistically significant, defined by a P value of 0.05, in more than one study. Given the issue of multiple testing in many reports, it is clearly advantageous when interpreting any purported association to have been replicated in an independent series. In some studies, the failure to demonstrate a relationship may be due to a lack of power. Genome-wide association (GWA) studies of cancer have demonstrated that the risk associated with individual polymorphic variants is quite modest (point estimates between 1.1 and 1.6 for an additive mode of inheritance). 76 Fewer than 20% of the studies we reviewed had 80% power to demonstrate a 2-fold difference in risk at the 0.05 significance level. To overcome this lack of power, we have undertaken a meta-analysis pooling the data from the published studies. There are, however, caveats to this statistical procedure. In any systematic review, publication bias is clearly of great concern. The most common scenario is that negative findings may go unreported. Furthermore, many studies do not describe the ethnicity of cases or controls, and it is assumed that each polymorphism is functional with respect to risk in each study population. These are likely to be the case with MTHFR C667T, and presumably also for GSTM1 and GSTT1, since the functional role of the variants are better characterized. If, however, the polymorphism is a neutral marker for another variant, the assumption may well not apply, since LD is often population dependent.
An important lesson from current studies is that greater attention should be paid to design of future studies. Considering the issues of concomitant disease, a number of the studies were based on a comparison of cases and hospital based controls. The use of healthy population controls is preferable, since it is conceivable that the polymorphism might confer susceptibility to non-cancer diseases. The issue of population stratification in case-control Polymorphisms acute lymphoblastic leukemia risk haematologica | 2010; 95 (8) studies and resulting false positive results is also of great concern. If population subdivisions exist, it is possible that associations will be found between disease and arbitrary markers that are unlinked to causative loci. Such associations occur because of population subdivision and nonrandom mating, leading to variation in the marker frequency within the population as a result of founder effects and/or genetic drift. The severity of spurious association becomes an increasing problem with increasing study size. To avoid this problem, it is essential that any potential confounding effect of population stratification be allowed for in the design and analysis of the study. This requires the identification of sub-populations in terms of factors that can influence both disease and marker allele frequencies. Provided cases and controls are well matched, differences in the frequency of genotypes will only be seen at predisposition loci. Hence, stratification can be detected by typing a series of unlinked markers chosen from a panel known to exhibit differences in allele frequency between populations. 77 The focus of this meta-analysis was strictly on results from candidate-gene association studies and did not take into account results from other analyses. We have attempted to review published analyses of the relationship between polymorphic variation and risk of ALL through several iterations of search criterion; it is, however, possible that we have missed some reported studies. As the number of articles on genetic variation on risk of ALL published in the past decade has increased considerably and continues to grow, we fully accept that this review will not long remain current but provides a snapshot of progress to date in the field.
The choice of tissue used in the 47 studies selected for analysis varied widely. The majority of them [29] [30] [31] [32] [33] [34] [35] [40] [41] [42] [43] [44] [46] [47] [48] [51] [52] [53] [54] [55] [56] 59, 60, 62, 63, 65, 67, 68, 70, 71, 74 were DNA extracted from peripheral blood, bone marrow or buccal samples collected at the time of diagnosis at the study center or with unspecified patient status. Five studies included samples from remission and those collected at diagnosis. [36] [37] [38] [39] 49, 69 Only six studies 45, 57, 61, 72, 73, 75 clearly stated that the samples were collected when the patients were in remission. The tissue origin for these studies varied from bone marrow, buccal swabs, Guthrie cards and peripheral blood. Four studies 50, 58, 64, 66 gave no clarification pertaining to sample origin. Studies that are based on DNA extracted from peripheral blood or bone marrow tissue obtained from non-remission patient samples may potentially contain somatic mutations that have the potential to confound association studies. Hence the results of such studies should be reassessed and accepted with caution. Due to the small number of studies that only used remission samples, such a screening criterion was not used in our current study selection.
Acute lymphoblastic leukemia is heterogeneous with respect to its underlying cellular and molecular biology, acquired genetic abnormalities and associated clinical responses to combination chemotherapy. 78, 79 It is, therefore, suspected that subtypes of B-or T-cell precursor ALL may not share a common etiology. To date only a very few studies have examined the relationship between variants and risk by subtype. Additionally these studies invite the issue of post hoc analysis.
All of the studies we have reviewed have been based on a candidate gene approach. It is becoming increasing clear from studies of cancer that without a clear understanding of tumor causalities the definition of what constitutes a candidate gene is inherently problematic, making an unbiased approach to loci selection highly desirable. The availability of high resolution LD maps and comprehensive sets of tagging SNPs, coupled with the development of highly efficient analytical platforms, allow GWA studies for disease associations to be conducted cost effectively. This approach is unbiased and does not depend upon prior knowledge of function or presumptive involvement of any gene in disease causation. Moreover, it avoids the possibility of missing the identification of important variants in hitherto unstudied genes. Very recently, results from the first GWA studies of ALL have become available and these studies have identified risk loci for ALL at IKZF1, ARID5B and CEBPE. 80, 81 The substantial evidence supporting these variants, including sizeable power and replication in large samples, indicates that the associations are highly robust. These data thus provide the first unambiguous evidence that common lowpenetrance susceptibility alleles contribute to the risk of developing childhood ALL. Furthermore, they provide novel insight into disease causation of ALL; notably all of the risk variants map to genes involved in transcriptional regulation and differentiation of B-cell progenitors. Given sub-optimal LD between many polymorphisms with tagging SNPs, especially those with low minor allele frequencies [MAF], the findings provide a strong rationale for directly evaluating variation in other B-cell developmental genes as risk factors.
Of the eight associations from the current meta-analysis which were nominally significant at the 5% threshold, one was a deletion. Of the seven SNPs one was directly genotyped as part of our GWA study of ALL (rs1051266; RFC1 G80A) and the CYP2E1*5B SNP rs3813867 was tagged by rs10857733 (R 2 =0.88). Both SNPs showed no association with risk (respective P values =0.81 and P=0.84).
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The search for polymorphic variants influencing the risk of ALL is a worthy enterprise; however, the studies that have been conducted to date have important lessons for the design and execution of future studies. Candidate gene analyses should be viewed as complementary to GWA studies, as they offer considerable advantages both in terms of statistical power and an ability to identify low frequency risk variants. Furthermore, many functional variants, such as the small scale insertion and deletions in carcinogen metabolism genes, are poorly captured by the tagging SNPs used in GWA studies. It is, however, clear that in addition to conducting studies using sample sizes commensurate with the detection of polymorphic risk factors, attention should be paid to study design to avoid problems of population stratification and other sources of potential bias in order to maximize the output of any study.
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